JP2016537364A - ラキニモドを用いた緑内障の治療 - Google Patents

ラキニモドを用いた緑内障の治療 Download PDF

Info

Publication number
JP2016537364A
JP2016537364A JP2016530937A JP2016530937A JP2016537364A JP 2016537364 A JP2016537364 A JP 2016537364A JP 2016530937 A JP2016530937 A JP 2016530937A JP 2016530937 A JP2016530937 A JP 2016530937A JP 2016537364 A JP2016537364 A JP 2016537364A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
laquinimod
package
agent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016530937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537364A5 (enExample
Inventor
ニューマン、ロン
エツィオーニ、レビタル
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2016537364A publication Critical patent/JP2016537364A/ja
Publication of JP2016537364A5 publication Critical patent/JP2016537364A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
    • B65D1/0207—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by material, e.g. composition, physical features
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016530937A 2013-11-15 2014-11-13 ラキニモドを用いた緑内障の治療 Withdrawn JP2016537364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904962P 2013-11-15 2013-11-15
US61/904,962 2013-11-15
PCT/US2014/065497 WO2015073697A1 (en) 2013-11-15 2014-11-13 Treatment of glaucoma using laquinimod

Publications (2)

Publication Number Publication Date
JP2016537364A true JP2016537364A (ja) 2016-12-01
JP2016537364A5 JP2016537364A5 (enExample) 2017-12-28

Family

ID=53058023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530937A Withdrawn JP2016537364A (ja) 2013-11-15 2014-11-13 ラキニモドを用いた緑内障の治療

Country Status (12)

Country Link
US (6) US20150141458A1 (enExample)
EP (1) EP3068395A4 (enExample)
JP (1) JP2016537364A (enExample)
KR (1) KR20160100302A (enExample)
CN (1) CN105960238A (enExample)
AU (1) AU2014348620A1 (enExample)
CA (1) CA2930113A1 (enExample)
EA (1) EA201690903A1 (enExample)
HK (1) HK1225971A1 (enExample)
IL (1) IL245373A0 (enExample)
MX (1) MX2016006256A (enExample)
WO (1) WO2015073697A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019182814A (ja) * 2018-04-17 2019-10-24 国立大学法人九州大学 生体リズム調整剤及び生体リズム調整用医薬組成物
JP2023509336A (ja) * 2019-12-19 2023-03-08 アクティブ バイオテック エービー 過剰血管新生に関連する眼疾患を治療する化合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3888650A1 (en) 2020-03-30 2021-10-06 Universität Regensburg Biochanin a diacetate for treatment of best1-related retinopathies
IL305997A (en) 2021-04-01 2023-11-01 Active Biotech Ab Laquinimod formulation for ocular use
CN119523881A (zh) * 2024-04-28 2025-02-28 中国人民解放军海军军医大学第二附属医院 一种s100a9抑制剂凝胶剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
WO2007005176A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
WO2010001257A2 (en) * 2008-07-01 2010-01-07 Actavis Group Ptc Ehf Novel solid state forms of laquinimod and its sodium salt
CN105616410A (zh) * 2009-07-30 2016-06-01 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
ES2731052T3 (es) * 2009-08-10 2019-11-13 Active Biotech Ab Tratamiento de la enfermedad de Huntington usando laquinimod
US20130029916A1 (en) * 2011-07-28 2013-01-31 Yossi Gilgun Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019182814A (ja) * 2018-04-17 2019-10-24 国立大学法人九州大学 生体リズム調整剤及び生体リズム調整用医薬組成物
JP2023509336A (ja) * 2019-12-19 2023-03-08 アクティブ バイオテック エービー 過剰血管新生に関連する眼疾患を治療する化合物
JP7730816B2 (ja) 2019-12-19 2025-08-28 アクティブ バイオテック エービー 過剰血管新生に関連する眼疾患を治療する化合物

Also Published As

Publication number Publication date
US20180140593A1 (en) 2018-05-24
IL245373A0 (en) 2016-06-30
US20170128436A1 (en) 2017-05-11
US20150141458A1 (en) 2015-05-21
US20170027927A1 (en) 2017-02-02
KR20160100302A (ko) 2016-08-23
AU2014348620A1 (en) 2016-06-16
EA201690903A1 (ru) 2016-10-31
CA2930113A1 (en) 2015-05-21
MX2016006256A (es) 2016-09-07
EP3068395A4 (en) 2017-07-12
US20170266179A1 (en) 2017-09-21
US20170368054A1 (en) 2017-12-28
HK1225971A1 (zh) 2017-09-22
CN105960238A (zh) 2016-09-21
EP3068395A1 (en) 2016-09-21
WO2015073697A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
JP6868014B2 (ja) 翼状片を治療するための組成物及び方法
US20240082266A1 (en) Compositions and methods for treating eyes and methods of preparation
EA025414B1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
JP2016537364A (ja) ラキニモドを用いた緑内障の治療
JP7705326B2 (ja) 眼疾患を処置するためのオキシメタゾリン組成物および方法
CN116211871A (zh) 具有神经保护性质的药物预防或降低受试者中的缺血-再灌注损伤的风险的用途
CN112367981B (zh) 用于将药剂无创地持续递送至眼部的液体储库
WO2017166888A1 (zh) 一种滴眼液及其制备方法与应用
AU2021340604B2 (en) Use of ester group-containing aromatic propionamide compound in preparation of medicine for treating dry eye syndrome
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
TWI868659B (zh) 無防腐劑的眼科藥物乳劑及其應用
CN105213418A (zh) 一种眼科术前用复方滴眼液及其制备方法
US20250381201A1 (en) Compositions and methods for treating eyes and methods of preparation
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
WO2023048174A1 (ja) 角膜疾患治療剤
AU2024274803A1 (en) Pharmaceutical composition for effectively delaying and treating myopia
KR20230021613A (ko) 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법
WO2025229951A1 (ja) 結膜充血を改善、緩和又は抑制するための組成物
BR122024023871A2 (pt) Formulações livres de conservantes oftálmicas aquosas farmaceuticamente estáveis, recipientes de uso único, bem como usos terapêuticos das ditas formulações
KR20230136579A (ko) 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법
CN118806757A (zh) 眼用制剂及其制备方法和用途
JP2024090835A (ja) 組織移行性を向上させるエピナスチン含有水性組成物
HK40031931B (zh) 羟甲唑啉组合物和用於治疗眼障碍的方法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20161013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171113

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180215